login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Implantable cardioverter defibrillators in patients nearing the end of life


Monday, 23 Apr 2012 14:02
Rachel Lampert
Rachel Lampert


Rachel Lampert, associate professor of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, USA, is giving the talk “When to consider ICD deactivation: End-of-life issues” at Heart Rhythm 2012 (9–12 May 2012, Boston, USA). She talked to Cardiac Rhythm News about this topic.


When would you consider deactivating an implantable cardioverter defibrillator (ICD) in a patient who was nearing the end of their life?

The short answer is that ICD deactivation should be considered whenever a patient wants it to be considered. Even if a patient was not near the end of their life, legally and ethically, an ICD should be deactivated if the patient wants it to be deactivated.

However, the longer answer is that all patients with an ICD should have an opportunity to discuss the option of deactivation before they reach the end of their life (ie, shortly after implantation). The issue of deactivation should also be proactively discussed with a patient when their condition worsens and a good time to discuss the issue is when other preferences, such advanced directives [living wills] or a do not resuscitate (DNR) orders, are being discussed. It is not up to the physician when an ICD “should” be deactivated. The role of the physician is to make sure the patient understands the consequences of keeping it active versus deactivating it—when the patient has all of the available facts, then the decision to deactivate is up to them. The decision should be made in the context of the person’s overall goals for his or her care at that time.


What are the indications that a patient is nearing the end of their life?


Often it is not clear, and this is one of the difficult issues in discussing deactivation and one of the reasons it is so important to discuss the issue early on. Other times, though, physicians can tell as a patient’s disease course progresses (whether it is their underlying heart disease or another disease such as cancer) that the disease is overcoming the patient and therapeutic options are exhausted.


You state that a good time to discuss deactivation is when advance healthcare directives are being discussed. Would you therefore encourage patients to include their wishes on ICD deactivation in these documents and generally why in your view are such directives important?


I would definitely encourage patients to write an advanced directive, and that they include their wishes regarding ICD deactivation. This is important, as is all advanced planning relating to ICD deactivation at the end of life, to avoid potential shocks, which are painful, as a person is dying.


If a healthcare provider has ethical or moral concerns about deactivation, what should they do?


The American Medical Association (AMA) code of ethics states that a physician should not be compelled to perform an action that goes against his moral beliefs. However, our document (1) stresses that the healthcare provider should not attempt to impose his beliefs on the patient and should help direct the patient to an alternate provider who can help him.


References

1. Lampert et al. Heart Rhythm Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing the end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7:1008–26




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

First leadless pacemaker approved in the USA
Wednesday, 06 Apr 2016
Medtronic has announced it has received US Food and Drug Administration (FDA) approval for its Micra Transcatheter Pacing System (TPS). The leadless device, which is 93% smaller than conventional ... First leadless pacemaker approved in the USA

St Jude Medical MultiPoint Pacing Technology could achieve 87% patient response rate according to clinical trial
Thursday, 05 May 2016
Results of St Jude Medical’s MultiPoint Pacing investigational device exemption clinical study have been presented during a late-breaking clinical trial session at the Heart Rhythm Society’s (HR... St Jude Medical MultiPoint Pacing Technology could achieve 87% patient response rate according to clinical trial

Features


Importance of obstructive sleep apnoea in EP
Thursday, 26 May 2016
Syed Rafay A Sabzwari and Dhanunjaya Lakkireddy (Kansas City, USA) review the importance of obstructive sleep apnoea (OSA) in electrophysiology and cardiology at large, as a secondary impact to an ... Importance of obstructive sleep apnoea in EP

Ventricular tachycardia ablation in Chagas disease
Friday, 13 May 2016
Guilherme Fenelon (Sao Paulo, Brazil) overviews the role of ablation of ventricular tachycardia in Chagas disease. He says: catheter ablation in Chagas disease remains a “challenging procedure,” ... Ventricular tachycardia ablation in Chagas disease

Profiles


George Van Hare
Wednesday, 04 May 2016
George Van Hare (The Louis Larrick Ward professor of Pediatrics and director, Division of Pediatric ... George Van Hare

Jonathan Kalman
Monday, 18 Jan 2016
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research ... Jonathan Kalman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions